Avid Bioservices (CDMO) Appoints Esther M. Alegria to its Board
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/17/2026
- Wall Street indexes slip as oil prices rise, retail results awaited
- Trump threatens to bomb Oman over Iran stance
- Why this Wall Street strategist says the "trade is long gold"
- U.S. EV market shows signs of bottoming out: Bernstein
- Micron rises as White House presses Apple to avoid Chinese memory chips
- Wall Street indexes slip as oil prices rise, retail results awaited
- Oil settles up over $2 as Iran war stalemate stokes supply concerns
- Trump threatens to bomb Oman over Iran stance
- BofA sees Micron EPS topping $230 by FY30, calls peak fears overblown
- L3Harris CEO steps down amid conduct review, shares drop
Avid Bioservices (CDMO) PT Raised to $29 at Stephens
July 1, 2021 6:26 AM EDTStephens analyst Jacob Johnson raised the price target on Avid Bioservices (NASDAQ: CDMO) to $29.00 (from $26.00) while maintaining a Overweight rating.... More
Avid Bioservices (CDMO) PT Raised to $29 at Craig-Hallum
June 30, 2021 8:49 AM EDTCraig-Hallum analyst Matthew Hewitt raised the price target on Avid Bioservices (NASDAQ: CDMO) to $29.00 (from $21.00) while maintaining a Buy rating.
The analyst commented, "With the stock hitting 52-week highs, expectations were high going into Avids Q4 earnings report, but in our... More
Avid Bioservices (CDMO) PT Raised to $27 at RBC Capital
June 30, 2021 6:12 AM EDTRBC Capital analyst Sean Dodge raised the price target on Avid Bioservices (NASDAQ: CDMO) to $27.00 (from $21.00) while maintaining a Outperform rating.... More
Avid Bioservices (CDMO) PT Raised to $28 at KeyBanc
June 30, 2021 4:40 AM EDTKeyBanc analyst Paul Knight raised the price target on Avid Bioservices (NASDAQ: CDMO) to $28.00 (from $22.00) while maintaining a Overweight rating.... More
Avid Bioservices (CDMO) Reports Q4 Loss of $0.04/sh
June 29, 2021 4:11 PM EDTAvid Bioservices (NASDAQ: CDMO) reported Q4 EPS of ($0.04), versus ($0.11) reported last year. Revenue for the quarter came in at $27.6 million versus the consensus estimate of $21.6 million.
GUIDANCE:
Avid Bioservices sees FY2021 revenue of $115-117 million, versus the consensus of $89.9... More
